ArticleValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2025

Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line Metastatic Urothelial Cancer in the United States.

Tanvi V Chiddarwar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.